Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc. is a fully integrated biopharmaceutical company focused on developing innovative medicines for people impacted by central nervous system (CNS) conditions. The company delivers scientific breakthroughs by identifying critical gaps in care and developing differentiated products with a focus on novel mechanisms of action that have the potential to transform patient outcomes. The innovative CNS portfolio is anchored by three U.S. Food and Drug Administration (FDA) approved commercial products: AUVELITY for the treatment of major depressive disorder (MDD), SUNOSI for the treatment of excessive daytime sleepiness (EDS) associated with obstructive sleep apnea or narcolepsy, and SYMBRAVO for the acute treatment of migraine with or without aura in adults. The company is also advancing a deep pipeline of novel product candidates in early- to late-stage development addressing a broad range of serious neurological and psychiatric conditions.

The company's industry is highly competitive and subject to rapid and significant technological change, with competitors including major pharmaceutical, specialty pharmaceutical, and biotechnology companies, academic institutions, and governmental agencies. Key competitive factors affecting the success of all product candidates are likely to be their efficacy, safety, convenience, price, the level of branded and generic competition, and the availability of reimbursement from government and other third-party payors. The company believes that its employees and consultants, scientific knowledge, technology, and development experience provide it with competitive advantages, though many competitors have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and marketing approved products.

The company generates revenue through the sale of its three FDA-approved commercial products: AUVELITY, SUNOSI, and SYMBRAVO. Total revenues from these three commercial products totaled $638.5 million ¹ for 2025, representing 66% annual growth compared to 2024. The company also generates royalty and milestone revenue from licensing agreements, including a licensing transaction with Pharmanovia to market SUNOSI in Europe and certain countries in the Middle East and North Africa. The company retains commercial rights in the United States and selectively partners outside of the United States to maximize the value of its products and product candidates.

AUVELITY (dextromethorphan and bupropion) was developed by the Company and approved by the FDA for the treatment of MDD in adults in August 2022. It was launched in the U.S. in October 2022 as the first and only oral, N-methyl-D-aspartate (NMDA) receptor antagonist approved for MDD in adults and the only oral antidepressant with rapid-acting efficacy reflected in the FDA label. Approximately 21 million people in the U.S. live with MDD. SUNOSI (solriamfetol) is a novel, oral, dopamine and norepinephrine reuptake inhibitor (DNRI), trace amine-associated receptor 1 (TAAR1) agonist, and 5-HT 1A agonist approved in the U.S. and Europe for the treatment of EDS in adult patients with obstructive sleep apnea or narcolepsy. The company acquired the U.S. rights to SUNOSI from Jazz Pharmaceuticals plc in May 2022, and the ex-U.S. rights (excluding certain Asian markets) in November 2022. Approximately 22 million adults and 185,000 people in the U.S. are affected by OSA and narcolepsy, respectively. SYMBRAVO (MoSEIC meloxicam-rizatriptan) is a novel, oral, rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor and 5-HT1B/1D agonist that was developed by the Company and approved by the FDA in January 2025 for the acute treatment of migraine with or without aura in adults. It was launched in the U.S. in June 2025. Approximately 39 million adults in the U.S. experience migraine.

The company's development pipeline includes AXS-05 (dextromethorphan and bupropion), currently being developed for the treatment of Alzheimer's disease (AD) agitation and smoking cessation. In December 2025, the FDA accepted for filing the Company's supplemental NDA (sNDA) for AXS-05 for the treatment of Alzheimer's disease agitation, granting Priority Review designation and a Prescription Drug User Fee Act (PDUFA) target action date of April 30, 2026. Solriamfetol is in Phase 3 clinical development for the treatment of attention deficit hyperactivity disorder (ADHD), MDD with EDS symptoms, binge eating disorder (BED), and excessive sleepiness associated with shift work disorder (SWD). AXS-12 (reboxetine) is a novel, oral, potent, highly selective investigational norepinephrine reuptake inhibitor (NRI) and cortical dopamine modulator being developed for the treatment of narcolepsy. In December 2025, the company received formal pre-NDA meeting minutes from the FDA supporting an NDA submission for AXS-12 for the treatment of cataplexy in narcolepsy. AXS-14 (esreboxetine) is a novel, oral, potent, highly selective investigational NRI being developed for the management of fibromyalgia. In 2025, the company submitted an NDA for AXS-14 for the management of fibromyalgia and received a Refusal to File (RTF) letter from the FDA. The company initiated the FORWARD study to address the FDA's feedback. AXS-17 (formerly AZD7325), a novel oral GABA A α2,3 receptor positive allosteric modulator, was acquired in November 2025 and is intended to be evaluated as a potential treatment for epilepsy.

In November 2025, the company acquired all the outstanding shares of Baergic Bio, Inc., providing global rights to AZD7325 (AXS-17) for a total upfront payment of $2.3 million ², with former Baergic shareholders and AstraZeneca AB eligible to receive contingent development, regulatory and sales-based milestone payments of up to $159.5 million ³ and tiered low double-digit to mid-teen royalties on potential global net sales. In December 2025, the company acquired the global rights to deuterium-stabilized S-bupropion from DeuteRx, LLC, with DeuteRx eligible to receive contingent development, regulatory and sales-based milestones of up to $523 million ⁴ and a tiered low single-digit royalty on potential global net sales. On May 8, 2025, the company entered into a loan agreement with Blackstone providing for loans in an aggregate principal amount of up to $570.0 million ⁵, consisting of a first lien senior secured term loan of $120.0 million ⁶ funded on the closing date, a $180.0 million ⁷ senior secured term loan available at the company's option, and a super senior revolving credit facility of up to $70.0 million ⁸. The proceeds were used to repay in full obligations under the Hercules Loan Agreement, resulting in a loss on debt extinguishment of approximately $10.4 million ⁹. In February 2025, the company entered into a settlement agreement with Teva resolving patent litigation related to AUVELITY, granting Teva a license to sell its generic version beginning on or after March 31, 2039 ¹⁰, if pediatric exclusivity is granted, or on or after September 30, 2038 ¹¹, if no pediatric exclusivity is granted. In May 2025, the company entered into a settlement agreement with Hetero Labs Ltd. permitting Hetero to begin selling its generic version of SUNOSI on September 1, 2040 ¹², or earlier under certain circumstances. In March 2025, the company entered into a settlement agreement with Hikma Pharmaceuticals USA, Inc. permitting Hikma to begin selling its generic version of SUNOSI on September 1, 2040 ¹³, or earlier under certain circumstances.

Total revenues from the company's three commercial products totaled $638.5 million ¹⁴ for 2025, representing 66% annual growth compared to 2024. The company's net loss was $183.2 million ¹⁵ for the year ended December 31, 2025. As of December 31, 2025, the company had an accumulated deficit of $1,306.0 million ¹⁶. Research and development expenses were $183.3 million ¹⁷ and $187.1 million ¹⁸ for the years ended December 31, 2025 and 2024, respectively.

A major growth vector is the potential approval and commercialization of AXS-05 for the treatment of Alzheimer's disease agitation. The FDA accepted the sNDA for filing in December 2025 with Priority Review designation and a PDUFA target action date of April 30, 2026 ¹⁹. The FDA previously granted Breakthrough Therapy designation for AXS-05 for the treatment of AD agitation in June 2020. AD affects approximately 7 million people in the United States, a number anticipated to double by 2060, and agitation affects up to 76% of people with AD. There is currently one FDA-approved pharmacological treatment for AD agitation, representing a significant unmet medical need and commercial opportunity.

Another growth vector is the expansion of solriamfetol into additional indications through Phase 3 clinical programs. The company is conducting Phase 3 studies in attention deficit hyperactivity disorder (ADHD), major depressive disorder (MDD) with excessive daytime sleepiness (EDS) symptoms, binge eating disorder (BED), and excessive sleepiness associated with shift work disorder (SWD). Over 22 million people in the U.S. are estimated to be affected by ADHD, with total annual societal excess costs associated with adult ADHD estimated at over $120 billion ²⁰. BED affects over 7 million people in the U.S., with approximately 28% of patients having received treatment in the prior year. An estimated 15 million working Americans may suffer from SWD. The company also plans to initiate a Phase 2/3 trial of AXS-05 in smoking cessation, where over 34 million adults in the U.S. smoke cigarettes and direct health care and lost productivity costs total approximately $300 billion annually in the U.S. alone ²¹.

Research and development expenses are expected to stabilize in the near term as certain development programs near completion while new development programs are initiated. The company expects to continue to incur substantial expenses and operating losses as it continues to develop current and future product candidates and expand sales, marketing, and manufacturing expenses related to commercialization.

The company does not currently own or operate any manufacturing facilities for the clinical or commercial production of its drug candidates, relying on third-party manufacturers. The company believes that its existing suppliers of active pharmaceutical ingredients and finished products will be capable of providing sufficient quantities to meet commercial and clinical trial supply needs. The company conducts periodic quality audits of their facilities.

Research and development expenses were $183.3 million ²² for the year ended December 31, 2025. The Blackstone Loan Agreement provides for loans in an aggregate principal amount of up to $570.0 million ²³, with a minimum liquidity covenant of $30.0 million ²⁴. The company does not disclose a specific capital expenditure plan or share repurchase authorization or dividend policy in the filing.

The company faces significant competition from other pharmaceutical and biotechnology companies, academic institutions, and research organizations. Many competitors have significantly greater financial resources and expertise. The company's commercial opportunities could be reduced or eliminated if competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, more convenient, or less expensive. Generic forms of the active ingredients of the company's product candidates are available and could be used off-label, which could adversely affect profitability.

The company is subject to extensive and ongoing regulatory requirements by the FDA and other regulatory authorities. The regulatory approval process is lengthy, time-consuming, and inherently unpredictable. Changes in marketing approval policies, enactment of additional statutes or regulations, or changes in regulatory review could delay or prevent approval of product candidates. The company also faces risks related to healthcare reform measures, including the Inflation Reduction Act of 2022, which established substantial changes to the Medicare program with drug pricing reforms and a Medicare Part D benefit redesign.

The company has incurred significant losses since inception, with a net loss of $183.2 million ²⁵ for 2025 and an accumulated deficit of $1,306.0 million ²⁶ as of December 31, 2025, and may never achieve or maintain profitability. The company is substantially dependent on the success of its three commercial products and cannot guarantee that any product candidates will successfully complete clinical trials, receive regulatory approval, or be successfully commercialized. The company faces significant competition from larger pharmaceutical and biotechnology companies with greater financial resources. The company relies on third-party manufacturers and service providers, and any failure to produce products in required volumes or comply with regulations could delay development or commercialization. The company's operating activities may be restricted by covenants under the Blackstone Loan Agreement, which provides for up to $570.0 million ²⁷ in aggregate principal amount and includes a minimum liquidity covenant of $30.0 million ²⁸; a breach could result in acceleration of all amounts outstanding.

Management's message emphasizes the company's transformation into a fully integrated biopharmaceutical company with three FDA-approved commercial products generating total revenues of $638.5 million ²⁹ in 2025, representing 66% annual growth compared to 2024. Key strategic priorities include advancing the deep pipeline of novel product candidates, particularly the sNDA for AXS-05 for Alzheimer's disease agitation with a PDUFA date of April 30, 2026 ³⁰, expanding solriamfetol into additional indications through Phase 3 programs, and continuing to commercialize AUVELITY, SUNOSI, and SYMBRAVO. Management believes that current cash is sufficient to fund anticipated operations into cash flow positivity based on the current operating plan.